Unnatural Products, Argenx Partner on Macrocyclic Peptides for Immune Disease

Unnatural Products, Argenx Partner on Macrocyclic Peptides for Immune Disease

When asked why he founded Unnatural Products (UNP), a developer of oral macrocyclic peptide therapeutics, Cameron Pye, PhD, attributes the decision at least in part to “being in the right place at the right time.” Pye and his co-founder Joshua Schwochert, PhD, met as doctoral students in the laboratory of Scott Lokey, PhD, at the University of California, Santa Cruz. Their research there exposed them to pre-competitive collaborations with pharma…

Argenx and Unnatural Products ink US$1.5bn macrocycle deal - European Biotechnology Magazine

California oral macrocyclic peptide specialist Unnatural Products, Inc. and Dutch-Belgian Argenx SE have formed a multi-target research collaboration aimed at developing oral macrocyclic peptide drugs with UNP's synthetic macrocycle platform. The post Argenx and Unnatural Products ink US$1.5bn macrocycle deal appeared first on European Biotechnology Magazine.